Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In partnership with the Wellcome Innovations Flagship Programme, MORU launched its Critical Care Asia Network project with its first investigators’ meeting on 19-20 Aug in Bangkok. The project will establish an Asian ICU network across 42 ICUs in nine countries and implement a setting-adapted electronic registry.

Critical care workshop attendees

Using the registry as well as qualitative methods, this project will evaluate the quality of critical care within the network, which will then lead into locally-led quality improvement interventions aiming to improve ICU performance and patient outcomes.

Building on methodology developed by our partners in Sri Lanka, Pakistan and India, the electronic registry will provide epidemiological data and map processes of care, involving caregivers and patients and family members. This will be complemented by qualitative evaluations of care processes, with the aim to empower healthcare teams to identify targets for improvement. Quality improvement interventions and research will be driven by priorities set by the network collaborators. The project works in close collaboration with the Flagship project lead by the OUCRU team on developing new low-cost technologies for ICUs in low/middle income countries. The network will also provide a platform for clinical trials planned for the next phase of the project. Follow the project on Twitter, as well via Rashan’s Twitter handle.

Above photo, collaborators at the Bangkok meeting (front row, from left): Dr Khamsay Detleuxay, Dr Nguyen Thien Binh, Dr Lakshmi Rangananthan, Dr Sophie Yacoub, Dr Rebecca Inglis, Dr Gyan Kayastha, Dr Mavuto Mukaka, Dr Victoria Adewole, Dr Louise Thwaites; (middle row): Dr Nguyen Thanh Nguyen , Dr Dong Phu Khiem, Dilanthi Gamage, Dr Lam Minh Yen, Dr Kathleen Thomas, Dr Bui Thi Hanh Duyen,  Dr Duong Bich Thuy, Dr Madiha Hashmi, Prof Ramani Moonesinghe, Dr Rozina Sultana, Abi Beane, Dr Syed Muhammad Muneeb Ali; (back row): Dr Arshad Taqi, Dr Dinh Minh Duc, Dr Rashan Haniffa, Dr Will Schilling, Ishara Udayanga, Prof. Marcus Schultz, Dr Swagata Tripathy, Prof Arjen M. Dondorp, Dr Muhammad Hayat, Dr Diptesh Aryal. Absent: Dr Steve Harris, Dr Bharath Kumar, Dr Jorge Salluh, Dr Meghan Lever, Dr Chris Pell, Dr Tamilarasu Kadhiravan, Dr Chairat Permpikul, Dr Ratapum Champunot, Dr Gentle Shrestha, Dr Rajyabardhan Pattnaik, Prof Guy Thwaites and Prof Yoell Lubell.

­- With thanks to Abi Beane for text and Jan Ariyalikit for photos

Similar stories

COPCOV now world’s largest COVID-19 pre-exposure prophylaxis trial

A 6-week recruitment burst at Aga Khan University in Pakistan led the way as COPCOV enrolment broke 1600 participants. Led by MORU, COPCOV is the world’s largest trial trying to determine if hydroxychloroquine and chloroquine prevent COVID-19.

How did people in Europe and SE Asia experience the first COVID-19 wave?

An international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues report the unequal impacts of public health measures, and the prevalence of ‘fake news’.

Recruitment surges in COPCOV COVID-19 prevention study

As high COVID-19 daily cases and highly transmissible variants risk overwhelming countries’ healthcare systems, COPCOV, the world’s last-standing large prophylaxis RCT, faces tight timelines to determine whether chloroquine/ hydroxychloroquine prevents COVID-19

Simple blood tests may help improve malaria diagnosis in clinical studies

About one-third of children diagnosed with severe malaria may instead have an alternative cause of illness, but simple blood tests could help researchers distinguish between the two and speed up research on new treatments.

OUCRU scientists identify combination of biological markers associated with severe dengue

Nguyen Lam Vuong, Sophie Yacoub & colleagues have identified a combination of biological markers in patients with dengue that could predict whether they go on to develop moderate to severe disease. Biomarkers are used to identify the state or risk of a disease in patients; these findings could aid the development of biomarker panels for clinical use and help improve triage and risk prediction in patients with dengue.

RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.